January 31, 2015     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Company
News Sectors
Automotive
Communications
Consumers
CSR
Electronics
Energy
Environment
Financial
Health & Med
Industrial
IT & Internet
Materials
Real Estate
Science & Research
Telecoms
Trade
Transportation
Departments
Annual Reports
Companies
News Alerts
News Search
Photo Gallery
Client Login
Japan Corporate News Network
About JCN
Privacy Policy
RSS  
Terms of Use
 
 
News Search

The results of your word search

Headline News

Eisai Launches Programs to Help Eliminate Lymphatic Filariasis By 2020 (Jan 31, 2012)

Eisai and Apollo Hospitals, HelpAge India to Improve Access to Medicines in India (Jan 18, 2011)

Eisai's New Sales Subsidiary in Canada (May 11, 2010)

Eisai to Sell Catheter Subsidiary to Terumo (June 19, 2008)

Takeda, Eisai Log Recurring Profit Falls in FY '07 (May 14, 2008)

Eisai Launches Sales Support Firm for Pharm. Machines in China (May 7, 2008)

M's Science and Eisai Sign Option Agreement for Sigma Agonist SA4503 (Mar 12, 2008)

Eisai Aiming to Achieve 1.5-T.-Yen Sales by FY 2016 (Mar 4, 2008)

Eisai to Buy Out U.S. Drug Maker MGI Pharma (Dec 10, 2007)

Eisai to Sell Kissei's Insulin Secretagogue in China (Sept 28, 2007)

more...
Press Release News

Eisai's Phase II Trial of Anticancer Agent Lenvatinib in Renal Cell Carcinoma Meets Primary Endpoint (Jan 30, 2015)

Eisai and Ajinomoto Pharmaceuticals Launch Branched-Chain Amino Acid Formula Livamin Oral Granules in The Philippines (Jan 26, 2015)

Eisai Listed In Global 100 Sustainability Index for Third Consecutive Year (Jan 23, 2015)

Phase III Trial of Antiepileptic Drug Perampanel as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures Conducted in Asia Including Japan and China Meets Primary Endpoint (Jan 5, 2015)

Eisai Listed for 13th Consecutive Year in FTSE4GOOD Index Series, an Index for Socially Responsible Investment (Dec 17, 2014)

Eisai Demonstrates Efficacy of Investigational Dual Orexin Receptor Antagonist E2006 in Sleep Initiation and Maintenance Data from Phase II Clinical Trial for Insomnia (Dec 10, 2014)

Eisai Presents Results from Phase III Trial of Antiepileptic Drug Fycompa as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures (Dec 9, 2014)

Eisai to Present New Research on Halaven (Eribulin) at 37th Annual San Antonio Breast Cancer Symposium (Dec 2, 2014)

Eisai Establishes Holding Company Eisai China Holdings Ltd. in China (Dec 1, 2014)

Eisai Opens New Parenteral Facility in China (Dec 1, 2014)

more...
 
CSR Report Download
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)